We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+1.5%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.24B
AUM Growth
-$1.73B
Cap. Flow
-$1.75B
Cap. Flow %
-141.12%
Top 10 Hldgs %
32.38%
Holding
322
New
31
Increased
40
Reduced
64
Closed
112

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$36.4M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$12.7M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$11.6M
4
CGEM icon
Cullinan Oncology
CGEM
+$9.06M
5
ALEC icon
Alector
ALEC
+$7.87M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$24M
2
CRIS icon
Curis
CRIS
+$13.8M
3
NBP
NovaBridge Biosciences American Depositary Shares
NBP
+$13.5M
4
PRTA icon
Prothena Corp
PRTA
+$11M
5
TVRD
Tvardi Therapeutics
TVRD
+$9.32M

Sector Composition

Rank Sector Weight
1 Healthcare 43.58%
2 Technology 0.24%
3 Consumer Staples 0.11%
4 Financials 0.06%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMVT icon
76
CALL
Immunovant
IMVT
$7.93B
$4.23M 0.34%
400,000
+38,300
+11% +$535K
NXTC icon
77
NextCure
NXTC
$20.4M
$4.15M 0.34%
43,073
+5,244
+14% +$537K
SRPT icon
78
CALL
Sarepta Therapeutics
SRPT
$1.64B
$3.89M 0.31%
50,000
-50,000
-50% -$3.79M
TGTX icon
79
PUT
TG Therapeutics
TGTX
$8.19B
$3.88M 0.31%
100,000
– –
NBP
80
NovaBridge Biosciences American Depositary Shares
NBP
$186M
$3.87M 0.31%
46,066
-203,934
-82% -$13.5M
ARKG icon
81
ARK Genomic Revolution ETF
ARKG
$1.53B
$3.79M 0.31%
40,961
+38,961
+1,948% +$3.31M
RDNT icon
82
RadNet
RDNT
$4.98B
$3.73M 0.3%
+110,647
New +$2.91M
KDMN
83
DELISTED
Kadmon Holdings, Inc.
KDMN
$3.63M 0.29%
936,615
– –
DBVT
84
DBV Technologies
DBVT
$813M
$3.55M 0.29%
32,273
– –
RNTX
85
Rein Therapeutics
RNTX
$64.8M
$3.5M 0.28%
140,000
– –
PHAT icon
86
Phathom Pharmaceuticals
PHAT
$928M
$3.39M 0.27%
100,000
– –
TCDA
87
DELISTED
Tricida, Inc. Common Stock
TCDA
$3.35M 0.27%
775,294
– –
XENE icon
88
CALL
Xenon Pharmaceuticals
XENE
$6.1B
$3.33M 0.27%
179,100
+29,000
+19% +$535K
SYBX
89
DELISTED
Synlogic
SYBX
$3.3M 0.27%
56,557
-42,951
-43% -$2.34M
FOLD
90
DELISTED
Amicus Therapeutics
FOLD
$3.29M 0.27%
341,500
– –
CMPS
91
Compass Pathways
CMPS
$1.47B
$3.25M 0.26%
85,063
-140,863
-62% -$5.03M
ALLK
92
PUT
DELISTED
Allakos
ALLK
$3.22M 0.26%
37,700
– –
PLRX icon
93
Pliant Therapeutics
PLRX
$65M
$3.17M 0.26%
108,700
– –
VKTX icon
94
Viking Therapeutics
VKTX
$3.88B
$3.14M 0.25%
524,754
-200,000
-28% -$1.19M
BLU
95
DELISTED
BELLUS Health Inc.
BLU
$3.14M 0.25%
1,010,545
+610,545
+153% +$2.33M
INCY icon
96
Incyte
INCY
$25.4B
$3.07M 0.25%
36,533
+13,521
+59% +$1.13M
BCAB icon
97
BioAtla
BCAB
$5.34M
$2.97M 0.24%
1,403
– –
CCXI
98
CALL
DELISTED
ChemoCentryx, Inc.
CCXI
$2.96M 0.24%
221,200
+21,200
+11% +$522K
TAOX
99
Tao Synergies Inc
TAOX
$24.1M
$2.96M 0.24%
+12,000
New +$2.81M
AVTX icon
100
Avalo Therapeutics
AVTX
$1.01B
$2.93M 0.24%
312
– –
2 3
4
5 6

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q2 2021 Portfolio in Review

As of Q2 2021, Ikarian Capital held 322 positions worth $1.24B, down 58% from $2.97B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Ikarian Capital withdrew a net $1.75B in Q2 2021, closing 112 positions and reducing 64 holdings. Its most notable exit was Curis, an estimated $13.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, up from 22% a quarter earlier, followed by Technology and Consumer Staples.

Against the trend, Ikarian Capital opened a new position in ChemoCentryx, Inc. worth $6.31M.

  • Ikarian Capital's largest Q2 2021 buy was ChemoCentryx, Inc.: 471,376 shares worth $6.31M.
  • Ikarian Capital added most to Biogen in Q2 2021, an estimated $36.4M increase.
  • Ikarian Capital's biggest Q2 2021 reduction was Eli Lilly, cutting an estimated $24M.
  • Ikarian Capital fully exited Curis in Q2 2021, selling an estimated $13.8M.
  • Ikarian Capital's ten largest holdings make up 32% of its $1.24B portfolio in Q2 2021.
  • Ikarian Capital opened 31 new positions and closed 112 in Q2 2021.
  • Ikarian Capital's portfolio value fell 58% quarter-over-quarter to $1.24B.

Based on Ikarian Capital's 13F filing for Q2 2021, filed 16 Aug 2021.